| State: | New Jersey |
|---|---|
| Address: | 121 River St, Hoboken, NJ 07030, USA |
| Postal code: | 07030 |
| Phone: | (201) 604-1130 |
| Website: | http://www.nuwiqusa.com/contact/ |
There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about Nuwiq, use the form below and your opinion, advice or comment will appear in this space.
P: 201-604-1130. Customer Service. For general questions about NUWIQ Antihemophilic Factor (Recombinant), reconstitution, product support, or this site, please contact Octapharma Customer Service.
P: 201-604-1130. Customer Service. What Octapharma product are you inquiring about?* Select One Wilate NUWIQ. Please describe your medical inquiry below.
LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma announced today that the European Medicines Agency has authorised an updated Summary of Product Characteristics (SmPC) for Nuwiq® that includes information on personalised prophylaxis in patients with haemophilia A. The updated...
Nuwiq® is indicated for the treatment and prophylaxis of bleeding in persons with hemophilia of all ages suffering with hemophilia A (congenital factor VIII deficiency). Nuwiq® can also be used in hemophilia A patients undergoing major or minor surgical procedures.
P: 201-604-1137 C: 201-772-4546 F: 201-604-1141. Medical Affairs. Phone*. What Octapharma product are you inquiring about?* Select One cutaquig NUWIQ wilate. Please describe your medical inquiry below.
Octapharma USA, Inc. 121 River Street, Suite 1201 Hoboken, NJ 07030 (201) 604-1130. Nuwiq Generic name: antihemophilic factor Drug class: miscellaneous coagulation modifiers.
Fax: (201) 604-1131. usmedicalaffairs@octapharma.com. NUWIQ. Bleeding disorders. OCTAGAM.
Fax: (201) 604-1131. usmedicalaffairs@octapharma.com. www.octapharma.com. Drugs. NUWIQ. Bleeding disorders.
NUWIQ ® is approved for the prevention and treatment of bleeding in people with haemophilia A. The updated PI includes immunogenicity data from the NuProtect study in previously untreated patients (PUPs).
Nuwiq® is produced in a human embryonic kidney cell line (HEK293F), which ensures human-specific post-translational protein processing. The mean half-life of Nuwiq® was 15.1-17.1 h in PTP studies with adults and adolescents, and 12.5 h in children aged 2-12 years.